



Sequella, Inc.
9610 Medical Center Drive
Rockville, MD 20850
Tele: 301-762-7776
www.sequella.com

NEWS RELEASE

September 18, 2006

DR. NACY TO RECEIVE LEADERSHIP AWARD

National Urban Technology Center to Honor Sequella CEO at September 20th Gala

ROCKVILLE, MD -- Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing products to treat diseases of epidemic potential, announced today its CEO, Dr. Carol Nacy, will be honored by The National Urban Technology Center (Urban Tech), a non-profit education corporation focused on the promotion of learning, academic performance, and workforce preparation among disadvantaged young people and adults, at their September 20th gala in Washington, DC. Dr. Shirley Ann Jackson, President of Rensselaer Polytechnic Institute, and The Honorable Alphonso Jackson, Secretary of the United States Department of Housing and Urban Development, will also receive such awards.

“This year Urban Tech's focus is on those leaders who are finding ways to close the gap in access to health, housing and education in low-income communities,” said Pat Brandsford, founder and President of the National Urban Technology Center. “Dr. Nacy and Sequella have taken the lead in healthcare using scientific research and preventive care to stem the spread of tuberculosis across the world. Her work will not only reduce the mortality rate among at-risk populations but also improve the quality of life for those less fortunate -- leveling the playing field between the ‘haves’ and the ‘have nots’.”

Entitled “A Time for Leadership,” the gala will recognize three area leaders for their support of the organization’s mission to “close the gap” in the delivery of services to families in need, as well as their contributions in the fields of education, housing, and healthcare. The September 20th event culminates a yearlong 10th anniversary celebration by the Urban Tech Center. The Center is headquartered in New York City and provides services to cities and communities in more than 40 states across the U.S.

“To be recognized for my corporate and scientific interest in new tools to combat tuberculosis in urban settings is a true honor,” said Dr. Carol Nacy. “The Urban Tech Center, together with its network of volunteers and partners, has improved the lives of thousands of people across the United States. They are to be commended for their work.”

Before founding Sequella, Dr. Nacy was Executive Vice President and Chief Scientific Officer of EntreMed from 1993 through its successful public offering in June of 1996. She is on the board of several companies and non-profits, including ASM Resources, Social and Scientific Systems, Women in Bio, and the Sequella Foundation. Prior to her business experience, she was a career scientist and Science Manager at the Walter Reed Army Institute of Research in Washington, DC.

About Sequella, Inc.

Sequella is a clinical-stage biopharmaceutical company focused on commercializing improved treatment paradigms for diseases of epidemic potential. The company leverages its global influence, infectious disease expertise, and diverse product portfolio to proactively address emerging health threats with significant market opportunity. For more information, please visit www.sequella.com

Forward-Looking Statement



Sequella, Inc.
9610 Medical Center Drive
Rockville, MD 20850
Tele: 301-762-7776
www.sequella.com

This press release contains forward-looking statements that are subject to risks and uncertainties, and includes statements that are not historical facts. Actual results could differ significantly from results discussed. Sequella disclaims any intent or obligation to update forward-looking statements, except as required by law.

MEDIA CONTACT: Alicia Moran Phone: 703-739-2424 x110.